Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...
Company
WuXi STA Breaks Ground on New US Manufacturing Site in Delaware
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement...
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million...
Henlius Pharma’s 2022 Interim Revenue Jumps 103.5% on Biosimilar Sales and Licensing
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in...
LongBio Pharma Raises Series A+ Funding to Advance Autoimmune Disease Drug Development
LongBio Pharma, a Shanghai-based next-generation macromolecular antibody developer, has raised tens of millions of renminbi...
Fosun Kite’s Yescarta CAR-T Therapy Secures New Clinical Trial Approval in China
Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd...
mProbe Raises Funds in Series B1 Round Led by AstraZeneca and CICC
Zhejiang-based mProbe, a protein and metabolomic marker discovery technology-based platform company, has reportedly raised an...
Huahai Pharma to Manufacture Pfizer’s Paxlovid for China Market
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has entered into a manufacturing and supply...
Recbio Completes Phase II Trial Enrollment for ReCOV COVID-19 Vaccine
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of enrollment...
Healsun Biopharm Raises USD 36.7 Million in Series B Financing for Antibody CDMO Expansion
China-based Hangzhou Healsun Biopharm Co., Ltd, an antibody and recombinant Contract Development and Manufacturing Organization...
Sirnaomics Initiates Phase I/II Trial for STP705 in Facial Squamous Cell Carcinoma
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the first subject systemic dosing in...
Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...
CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...
Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech
China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....
Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China
The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...
GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement
Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...
Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Baidu Health’s Precision Matching Engine Powers Public Hospitals
China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...
WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...